Jeremy Ackermann, DO
Family Medicine · Moncks Corner, SCNPI 1417983982
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,290 of the $3,265 with a category attached, or 70.1%. 28 manufacturers reported payments, led by Shionogi Inc at 29.9% of the total. 2025 is the largest year on record at $1,351, 4.3 times the $316 reported in 2019.
Across 114 payments — averaging $28.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shionogi Inc$975
- Novartis$315
- Abbott$280
- Novo Nordisk$236
- Pfizer$185
- Amgen$157
- plus $1K from 22 others
Across 123 payments — averaging $61,397 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$6.7M
- Pfizer$612K
- Vertex$98K
- Sanofi US Services Inc.$53K
- Amgen$47K
- Eli Lilly$15K
- plus $16K from 3 others
What the payments were for
- Consulting fees$97530%
- Food & beverage$2,29070%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shionogi Inc | 1 | $975 |
| Novartis | 17 | $315 |
| Abbott | 13 | $280 |
| Novo Nordisk | 13 | $236 |
| Pfizer | 12 | $185 |
| Amgen | 8 | $157 |
| AbbVie | 9 | $151 |
| Boston Scientific | 2 | $129 |
| GSK | 7 | $127 |
| Medtronic | 1 | $121 |
| Dexcom, Inc. | 3 | $97 |
| E.r. Squibb & Sons, L.L.C. | 4 | $61 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $56 |
| Lilly USA, LLC | 3 | $56 |
| Astellas Pharma US Inc | 3 | $44 |
| Bayer | 2 | $35 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 1 | $30 |
| Phathom Pharmaceuticals, Inc. | 1 | $25 |
| Boehringer Ingelheim | 1 | $25 |
| Coloplast | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Inari Medical, Inc. | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- S-217622$975
- INTERSTIM$121
- GENERAL PAIN MANAGEMENT$115
How this compares
$3,265 in reported general payments places this provider in the 80th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 190 | $173,709 |
| OzempicSemaglutide | 123 | $160,490 |
| TrulicityDulaglutide | 118 | $151,981 |
| EliquisApixaban | 140 | $112,369 |
| MounjaroTirzepatide | 73 | $99,303 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $72,498 |
| LinzessLinaclotide | 53 | $48,436 |
| ProliaDenosumab | 25 | $43,068 |
| XareltoRivaroxaban | 45 | $40,528 |
| Repatha SureclickEvolocumab | 49 | $37,440 |
| TradjentaLinagliptin | 24 | $26,616 |
| Tresiba Flextouch U-200Insulin Degludec | 31 | $25,747 |
| JanumetSitagliptin Phos/Metformin Hcl | 19 | $25,068 |
| JanuviaSitagliptin Phosphate | 25 | $24,411 |
| Humalog Kwikpen U-200Insulin Lispro | 14 | $24,114 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $56 | $251,283191 claims |
| Boehringer IngelheimJardiance, Tradjenta | $25 | $200,324214 claims |
| Novo NordiskOzempic | $236 | $160,490123 claims |
| PfizerEliquis, Premarin | $185 | $118,424154 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $127 | $96,114100 claims |
| AbbVieLinzess, Ubrelvy | $151 | $62,96167 claims |
| MerckJanumet, Januvia | $11 | $49,47944 claims |
| AmgenProlia | $157 | $43,06825 claims |
| Johnson & JohnsonXarelto | $15 | $40,52845 claims |
| Astellas Pharma US IncMyrbetriq | $44 | $18,75128 claims |
| Sanofi-aventis U.S. LLCMultaq | $21 | $9,63312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Moncks Corner
- Nathan AverillMoncks Corner$25K
- Stephen BruntonWinnsboro$1.3M
- Richard WilkesMt Pleasant$216K
- Andrew MartinColumbia$205K
- Ada StewartColumbia$186K
- Jeffrey BroderNorth Augusta$140K
- Terry NagelColumbia$112K
- Katherine JohnsonGreenwood$80K
- Scott SmithMount Pleasant$68K
- Jennifer StolinSummerville$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.